Background-Biomarkers
T he prevention of cardiovascular disease (CVD) is based on accurate risk assessment. Since the introduction of the Framingham Risk score, many additional cardiovascular risk biomarkers have been identified and validated, including high-sensitivity CRP (hs-CRP) 1, 2 and coronary artery calcium (CAC). [3] [4] [5] [6] [7] Several studies have shown that CAC provides the most improvement in risk reclassification beyond traditional cardiac risk factors. [8] [9] [10] The American College of Cardiology/ American Heart Association guidelines from 2010 gave class IIa recommendations to CAC and hs-CRP testing for cardiovascular risk prediction in intermediate-risk, asymptomatic individuals. 11 The 2013 American College of Cardiology/ American Heart Association cardiovascular risk guidelines suggest that individuals with elevated CAC or hs-CRP be considered for statin therapy if they would not qualify for treatment based on calculated risk alone. 12 
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Although the use of CAC has been shown to predict future cardiovascular events and to add predictive information to standard risk assessment, little is known about its effects in real-world practice. 13 Since 2007, The American College of Cardiology/American Heart Association guidelines have not recommended further noninvasive diagnostic testing based only on an elevated CAC score.
14 CAC is intended to inform the use of medications, such as statins and aspirin, for the primary prevention of cardiovascular events, but an elevated CAC might persuade patients and clinicians to pursue subsequent diagnostic testing for coronary artery disease (CAD). Changes in testing and in use of therapeutic interventions as a result of CAC testing may affect rates of major CVD events, such as mortality, myocardial infarction (MI), and stroke.
A prospective randomized trial comparing CAC versus no CAC among healthy volunteers (mean age, 58 years) found no significant differences in 4-year use of lipid-lowering medications, stress tests, coronary angiography, revascularization, MI, or mortality. 15 However, the patients assigned to CAC did have a greater decrease in low-density lipoprotein cholesterol level, as well as lower systolic blood pressure and waist circumference. The St Francis Heart Study randomized healthy volunteers (mean age, 59 years) with CAC scores above the 80th July 2014 percentile to low-dose atorvastatin and vitamins C and E. The study was likely underpowered to detect a significant reduction in CVD events overall at 4 years (6.9% versus 9.9%; P=0.08). 16 The prevalence of abnormal CAC scores increases with age, but the effect of CAC testing on healthcare use and spending in an older population, such as Medicare beneficiaries, is not known. Furthermore, it remains uncertain whether treatment decisions after CAC, when compared with other risk markers, lead to meaningful changes in rates of cardiovascular events. Therefore, we sought to compare healthcare use, spending, and clinical outcomes in asymptomatic Medicare beneficiaries, who were evaluated with CAC versus risk biomarker hs-CRP or standard lipid screening.
Methods

Data
This study used Medicare claims records between 2005 and 2011 from a 20% random sample of traditional, fee-for-service beneficiaries. Healthcare use and spending were derived from carrier, inpatient, and outpatient claims. Diagnosis codes used the International Classification of Diseases-Ninth Revision (ICD-9), Clinical Modification. Procedures were identified by ICD-9-Clinical Modification codes in the inpatient claims files and by Current Procedural Terminology (CPT) codes in the carrier and outpatient claims files. Medicare enrollment information, demographic data, residence state, and date of death for decedents were obtained from denominator files. On the basis of state of residence, each patient was assigned to 1 of 4 US Census regions (Northeast, South, Midwest, and West).
Study Population
We used CPT codes to identify beneficiaries who received CAC To identify lipid screening, we included only those CPT codes with a primary ICD-9 diagnosis code for cardiovascular screening (V81.0, V81.1, and V81.2); since 2005, this combination of CPT and ICD-9 coding is required for Medicare coverage as a preventive service. To identify CAC-specific testing, we excluded patients who had CAC testing within 1 day of coronary computed tomographic angiography.
The date of the first CAC, hs-CRP or lipid screening test was termed the index test date. If ≥1 test was ordered on the index date (<1% of all episodes; Table I in the Data Supplement), the index test type was assigned using the hierarchy CAC>hs-CRP>lipid screening. Patients had to be enrolled in Medicare for ≥6 months before the index date to be included.
To focus on asymptomatic individuals without a history of CVD, we excluded beneficiaries with an index test for angina (ICD-9 413.x), chest pain (786.5x), ischemic heart disease (410.x, 411.x, 412.x, and 414.x), or shortness of breath (786.0x) and beneficiaries with any previous diagnoses, procedures, or hospitalizations for CVD in the 6 months before the index date (Table II in the Data Supplement for CPT and ICD-9 codes).
Our initial analysis sample consisted of 3 groups of patients according to index test. For the comparative analysis, we created 2 matched cohorts using propensity-score methods. Propensity scores offer a way to balance groups and to reduce bias in observational studies by matching treatment and control patients based on a set of covariates. We matched each patient who received CAC with 1 patient who received hs-CRP, and with 1 patient who received lipid screening, using a unique propensity score. The variables included to calculate each propensity score were tobacco use, hyperlipidemia, 30 Elixhauser comorbid conditions, 17 and total Medicare spending 6 months preceding the index date; dual Medicaid coverage; race/ethnicity; sex; age; US Census region; and specialty of the physician ordering the index test (Primary Care [General Practitioner, Family Medicine, and Internal Medicine], Cardiology, and Other). We used a greedy algorithm to match patients, which first matched propensity scores at 7 digits, then at 6 digits, down to a 2-digit match (0.01 level). 18 We required those patients be matched on index year.
Outcomes
The outcomes of interest were receipt of noninvasive cardiac stress testing, coronary angiography, coronary artery revascularization, first hospitalization for acute MI or stroke, death from any cause, and total and CVD-related spending. We tracked the use of cardiac tests and procedures ≥180 days of follow-up to capture follow-up tests and procedures resulting from the index test. We tracked clinical outcomes (mortality, MI, and stroke) until December 31, 2011, using the denominator files to determine all-cause mortality. We also tracked spending over 3 years of follow-up and defined CVD-related spending using the same criteria listed earlier to define CVD.
Statistical Analysis
Differences in baseline patient characteristics for each cohort were assessed using the χ 2 test for categorical variables and Student t test for continuous variables.
After propensity-score matching, we calculated the incidence rate of cardiac testing, cardiac procedures, and clinical outcomes as the number of events per 100 person-years of follow-up. We used Kaplan-Meier survival curves to summarize the composite outcome of all-cause mortality, MI, or stroke. We performed survival analyses of the matched data using Cox proportional hazards models, with stratification on the matched pairs. For outcomes other than mortality, we censored data at the time of death or at the end of claims followup on December 31, 2011, whichever came earlier. The proportional hazards assumption was met for all survival models. 19 We examined all index testing-by-covariate interactions for receipt of noninvasive cardiac testing. We focused our analysis of interactions on noninvasive cardiac testing because this outcome should have the strongest correlation with cardiovascular risk assessment. Clinical guidelines assign a class IIb recommendation (may be considered) to noninvasive cardiac testing in asymptomatic patients, and an elevated CAC score may influence ordering. 20 To examine the relationship between receipt of CAC and subsequent healthcare expenditures at 3 years, which are right-skewed in distribution, we used a generalized linear model with a log link and γ distribution specified for the error term. We repeated the analysis after capping costs at $100 000, $200 000, and $500 000.
We conducted an additional sensitivity analysis by comparing CAC versus risk biomarker lipoprotein-associated phospholipase A2. 21 We performed all hypothesis tests on a 2-sided basis with an α=0.05 and report no P values <0.001. We used SAS version 9.1.3 and Stata version 12.1 to perform statistical analyses. The Institutional Review Board of the Stanford University School of Medicine approved this study.
Results
Initial Analysis Sample
We identified 623 651 Medicare beneficiaries who received CAC, hs-CRP, or a screening lipid panel between 2006 and 2011. After all exclusion criteria were applied ( Figure I in the Data Supplement), 4184 patients had CAC, 261 356 patients had hs-CRP, and 118 093 patients had lipid screening. Patients who received CAC were younger than beneficiaries who received hs-CRP and lipid screening (Table 1) ; 41% were men and 92% were white. Patients who received CAC had more comorbidities than those who underwent lipid screening, but had less diabetes mellitus than those who received hs-CRP. Approximately 40% of CAC tests were ordered by a cardiologist when compared with 6.5% of hs-CRP and <1% of lipid screening.
Propensity-Score-Matched Cohorts
We matched 99.9% of patients with CAC with a patient who received hs-CRP, and 75% of patients with CAC with a patient who received lipid screening. Baseline clinical characteristics of the propensity-score-matched cohorts were balanced with all demographics variables, comorbid conditions, Medicaid enrollment, region, and ordering physician specialty ( 
Spending
Total spending after CAC was ≈$8000 higher than after lipid screening ($48 439 versus $40 132; P<0.001) but was not significantly different when compared with patients receiving hs-CRP (Table 4) . CVD-related spending was higher after CAC than after hs-CRP ($6525 versus $4432; P=0.005) and lipid screening ($6500 versus $3073; P<0.001). The differences in CVD-related spending remained statistically significant after trimming outliers (Table III in 
Clinical Outcomes
During the median 3-year follow-up (interquartile range, 1.4-4.3 years), the incidence rate of the composite outcome of death, MI, or stroke was low: in the CAC versus hs-CRP cohort, 122 events (1.1 per 100 person-years) versus 166 events (1.5 per 100 person-years) and in the CAC versus lipid screening cohort, 103 events (1.2 per 100 person-years) versus 120 events (1.4 per 100 person-years). Event-free survival was higher after CAC when compared with hs-CRP (94.4% versus 92.7%; P=0.008; Figure 2 ). Although there was a trend toward increased event-free survival after CAC when compared with lipid screening, it was not statistically significant (94.1% versus 93.2%; P=0. 22) . Beneficiaries who received CAC had a 26% lower risk of CVD events than beneficiaries who received hs-CRP (HR, 0.74, 95% CI, 0.58-0.94, P=0.017; Table 5 ).
The results of the secondary analysis comparing CAC with lipoprotein-associated phospholipase A2 were similar to the CAC/lipid screening analysis. In the propensity-matched cohort (n=5388), noninvasive diagnostic testing was twice as likely (HR, 2.55, 95% CI, 2.20-2.96, P<0.001) after CAC; coronary angiography and revascularization were also more common Comparisons of CAC with hs-CRP, and CAC with lipid screening, were statistically significant (P<0.05) by χ 2 or t test, unless specified by asterisks. CAC indicates coronary artery calcium; and hs-CRP, high-sensitivity CRP.
(Table IV in the Data Supplement). CVD-related spending was $3322 higher after CAC (P<0.001; Table V in the Data Supplement). However, the combined end point of mortality, MI, or stroke was not significantly lower after CAC (HR, 0.93, 95% CI, 0.45-1.87, P=0.83; Table VI in the Data Supplement).
Discussion
In this propensity-score-matched observational analysis, we found that Medicare beneficiaries who underwent CAC scoring without apparent symptoms or history of CVD were 2× to 4× more likely to receive additional cardiac procedures, including diagnostic testing and coronary artery revascularization, than beneficiaries assessed with hs-CRP or standard lipid screening. The increased use of subsequent procedures after CAC was associated with a $2093 to $3427 increase in CVD-related expenditures. Absolute rates of death, MI, and stroke were low during a median of 3-year follow-up, yet there was a 27% lower risk after CAC testing when compared with hs-CRP, and a nonsignificant trend toward decreased events after CAC testing when compared with lipid screening.
Although risk assessment for CAD should take place before 65 years of age, the use of CAC has grown steadily in the Medicare population. CAC is a strong predictor of cardiovascular events even in the elderly where the underlying prevalence of coronary atherosclerotic plaque burden is high. Asymptomatic elderly participants in the Rotterdam Study with calcium scores ≥400 were ≥5× as likely (relative risk, 5.4, 95% CI, 1.7-17.5) to have an MI in the subsequent 3 years than patients with a score of 0 to 100. 23 Despite the predictive information provided by CAC, there has been little clinical evidence that preventative interventions based on high CAC score alone, such as statin therapy, The cohorts matching CAC to hs-CRP, and CAC to lipid screening, were each generated using a unique propensity score. CAC indicates coronary artery calcium; and hs-CRP, high-sensitivity C-reactive protein.
improve clinical outcomes. 16 The St Francis Heart Study found that among healthy volunteers with a CAC>400, statin use was associated with fewer cardiovascular events at 4 years (8.7% versus 15.0%; P=0.046), but this was a post hoc analysis. 16 The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial demonstrated that the use of rosuvastatin in asymptomatic patients (median age, 66 years) with elevated hs-CRP levels reduced the incidence of major cardiovascular events at 2 years (0.45 versus 0.85 per 100 person-years) 2 ; however, an analysis of patients from the MultiEthnic Study of Atherosclerosis who met inclusion criteria for the JUPITER trial demonstrated that CAC>100 helped to risk stratify to guide statin therapy, whereas hs-CRP>2 mg/L did not predict risk of CVD events. 24 The results of our study suggest that more aggressive cardiac evaluation and treatment after CAC testing may, in fact, be associated with better patient outcomes. However, our claims-based analysis did not permit tracking of medication use after index testing. We cannot determine whether the association between CAC and improved clinical outcomes was because of more aggressive cardiac testing and intervention or more intensive medical therapy, including aspirin and statin use, and lifestyle changes. Several studies have shown that patients with elevated CAC are more likely to be prescribed aspirin and statin therapy 25, 26 and are more likely to engage in dietary changes and exercise. 27 Few studies have evaluated the use and spending after use of CAC, and none have compared clinical consequences of CAC with other biomarkers. The Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research (EISNER) trial randomly assigned 2137 healthy volunteers to CAC screening or no screening with risk factor counseling. 15 At 4 years, there was no overall difference in medical care use and expenditures between volunteers assigned to CAC or not, but rates of cardiac stress testing and revascularization were much higher in patients with high CAC scores when compared with those with a CAC score of zero. Our study population was older than the EISNER population and, therefore, more likely to have higher CAC scores, which may explain the large increases in the use and spending we observed after CAC testing. For example, a nonsmoking 65-year-old man with a total cholesterol of 130 mg/dL, high-density lipoprotein of 40 mg/dL, and no diabetes mellitus or hypertension has at least an intermediate risk of MI at 10 years (9% Framingham Risk score; 9.6% American College of Cardiology/American Heart Association pooled risk). To explore these study population differences further, we repeated our analysis by focusing on the youngest beneficiaries, <70 years of age. CAC in this group (mean age, 67.5 years) was also associated with more testing, revascularization, and spending, with a trend toward improved event-free survival (Tables  VII and VIII in the Data Supplement) .
An important caveat of this analysis is the inherent difference between CAC and the comparison groups, laboratory-based hs-CRP and lipid screening. 28 CAC is a direct, imaging-based measurement of the burden of coronary atherosclerosis, whereas the other tests are serum biomarkers to assess vascular inflammation Univariate proportional hazards models account for matched data. Any tests indicate any noninvasive cardiac testing; CABG, coronary artery bypass grafting; CAC, coronary artery calcium; Cath, coronary angiography; CCTA, coronary computed tomographic angiography; CI, confidence interval; ETT, exercise treadmill test; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein; MPS, myocardial perfusion scintigraphy; PCI, percutaneous coronary intervention; and TTE, stress transthoracic echocardiography. or dyslipidemia, contributors to the development of atherosclerosis and subsequent cardiovascular events. In practice, physicians may be more heavily influenced by findings derived from a coronary artery image rather than from a blood test.
We found a 2-to 5-fold increase in noninvasive testing after CAC in the primary care population although they did not carry a higher burden of atherosclerotic disease: the incidence of MI, stroke, or all-cause mortality among patients with CAC of primary care physicians was 1.2 per 100 person-years versus 1.1 per 100 person-years among patients of cardiologists. However, CAC did not as greatly influence the use of noninvasive cardiac testing among cardiology patients; 1 potential explanation is that the higher prevalence of CAD limited the influence of CAC on the cardiologists' decision to pursue further diagnostic testing. The differential effect of CAC on decision making across physician specialties warrants further evaluation. There are several limitations for this study. Because of the lack of information on medication use and traditional CVD risk factors, including blood pressure and cholesterol levels, propensity-score matching may not have entirely balanced CVD risk among patients receiving CAC and hs-CRP or lipid screening. Also, we did not formally adjust for multiple comparisons; a Bonferroni adjustment was too conservative given the correlation among outcomes. Although <5% of patients in our study received percutaneous coronary intervention or coronary artery bypass grafting within 180 days of index testing, we also cannot rule out the possibility that some patients had angina at the time of CAC testing, for which downstream diagnostic testing and revascularization may be appropriate. Beneficiaries may have also had CAD before the 6-month exclusion window. We also have no information about the physicians who ordered the risk biomarkers in this study; early adopters of new technology, such as CAC, may be more aggressive in their use of subsequent cardiac interventions. Patient preferences for CAC, a highly advertised procedure, may also drive use. We have attempted to address these concerns by excluding beneficiaries with a previous or current diagnosis of CAD and by use of propensity-score matching. The fact that increased use and spending and decreased clinical events were observed in several comparative analyses with beneficiaries that, at baseline, were both sicker (hs-CRP) and healthier (lipid screening) than CAC beneficiaries lend support to the view that our results are robust.
Our analysis was performed among fee-for-service Medicare beneficiaries and did not include individuals in prepaid health plans who may have lower use of cardiac tests and procedures. We could not assess the diagnostic performance of the noninvasive tests, the appropriateness of the invasive procedures performed, medication changes, or the effect of procedures on the patients' quality of life. Variable reimbursement of CAC by Medicare also limited our evaluation; Medicare's National Coverage Determination permits CAC to be covered as a diagnostic service, but local Medicare contractors have discretion to determine whether CAC is covered for screening purposes.
CAC measured by computed tomography was developed ≥20 years ago and has only recently demonstrated its ability to improve cardiovascular risk assessment, with relatively low cost and increasingly less radiation. 29 Our data suggest that the use of CAC among asymptomatic Medicare beneficiaries may increase diagnostic testing, invasive cardiac procedures, and CVD-related spending, yet may also be associated with a small decrease in rates of major cardiovascular events. This decrease in events may be related to medication and lifestyle changes in response to an elevated CAC score or an abnormal stress test or the direct effect of revascularization. A prospective trial randomizing intermediate-risk individuals to cardiovascular risk assessment with CAC or other risk biomarkers is ultimately warranted to assess the comparative effectiveness of these tests.
Sources of Funding
This study was funded by the American Heart Association (Dallas, TX) and the Stanford Cardiovascular Institute (Stanford, CA).
Disclosures
The Stanford Division of Cardiovascular Medicine has a cardiovascular MRI research agreement with GE Healthcare, Inc. Univariate proportional hazards models account for matched data. CAC indicates coronary artery calcium; CI, confidence interval; HR, hazard ratio; hs-CRP, highsensitivity C-reactive protein; and MI, myocardial infarction.
CLINICAL PERSPECTIVE
Coronary artery calcium (CAC) has been shown to predict future cardiovascular events and add predictive information to standard risk assessment, but little is known about its effect in real-world practice. The present study used Medicare claims from 2006 to 2011 to compare the use, spending, and clinical outcomes in asymptomatic beneficiaries evaluated with CAC versus cardiovascular biomarker high-sensitivity C-reactive protein or standard lipid screening. We found that Medicare beneficiaries who underwent CAC testing were 2× to 4× more likely to receive additional cardiac procedures at 180 days, including diagnostic testing and coronary artery revascularization, than beneficiaries assessed with high-sensitivity C-reactive protein or standard lipid screening. Primary care physicians were more likely to order additional testing after CAC when compared with cardiologists. CAC was associated with higher cardiovascular disease-related expenditures, as well as a small improvement in clinical outcomes when compared with high-sensitivity C-reactive protein. This may be because of more aggressive cardiac testing and intervention or more intensive medical therapy, including aspirin and statin use, and lifestyle changes. A prospective trial randomizing intermediate-risk individuals to cardiovascular risk assessment with CAC or other risk biomarkers is warranted to assess the comparative effectiveness of these tests truly.
